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Abstract
Over the last 30 years dermatological approaches to diagnosis and management of melanocytic
lesions have been revolutionized by the introduction of dermoscopy. Continuous improvements are
being made in applying the technique, mostly in melanoma diagnosis, follow-up of melanocytic lesions
and nevogenesis. Identification of new dermoscopic criteria, such as the dermoscopic island and the
blue-black color for thin and nodular melanoma, respectively, further add two new weapons in the
dermoscopical armamentarium for diagnosis of otherwise featureless melanoma. Recent advances
show that short-term, 3-month, follow-up is the optimum time interval to identify minimal changes in
initially featureless melanomas. Nevertheless, long-term follow-up is still useful for the recognition of
changes in melanomas with a very low-rate of growth. Dermoscopy greatly improves diagnosis and
early excision of melanomas and reduces the number of unnecessary excisions.
Introduction
In the pre-dermoscopic era, melanoma diagnosis was
based only on clinical morphology and on the simple
“ABCD” rule (asymmetry, border irregularity, color,
diameter) [1,2]. Dermoscopy or dermatoscopy [3,4] is a
non-invasive technique that consists of viewing pigmen-
ted skin lesions through a hand-held lens,adermatoscope
or a video imaging system [5]. This procedure allows
physicians to observe structures and colors not otherwise
visible to the unaided eye, increasing melanoma diag-
nostic accuracy by up to 35% [3,6,7]. The conventional
dermoscopic diagnosis is based on the assessment of
specific criteria and on the application of different
diagnostic algorithms [5]. In recent years, polarized light
dermatoscopes gradually overtook non-polarized light
devices, which were introduced in the 1990s and are still
used today [8].
Since its introduction in the mid-1980s, and thanks to
more than 1500 publications, dermoscopy has developed
and dramatically become a well-established, routine
technique in many European countries and Australia
[9,10]. Nevertheless, in other countries, like the United
States, dermoscopy still struggles to be accepted in daily
clinical practice [11]. Herein, we reviewed the most recent
importantadvancesindermoscopyofmelanocyticlesions
published in the last three years in English literature.
Other applications of dermoscopy for non-melanoma
skin cancers and other skin conditions are beyond the
scope of this review [6,12,13].
New advances in melanoma diagnostics
First, dermoscopy is not too time-consuming. The time
for dermoscopic examination of nevi is basically double
that required for a naked-eye examination (142 vs 70
seconds), but still under 3 minutes - a reasonable time
for a correct skin cancer screening [14].
Dermoscopyreduces the number of unnecessaryexcisions
[3,15,16], thanks to the improvement of diagnostic
accuracy [3]. Argenziano et al. showed that, in specialized
clinical settings, the introduction of dermoscopy leads to
a reduction of excised nevi and to an increased number
of diagnosed and excised melanomas [16]. With
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the malignant/benign ratio of excised lesions [15,17] and
even non-clinicians can identify suspicious lesions [18]
simply by applying a simple method like the AC rule
(asymmetry and color variation) [19].
Recently, several groups analyzed the most commonly
useddermoscopicalgorithms [7,20,21].Haenssle etal.[7]
and others [22] revised the 7-point checklist in a 10-year
prospective study and found this method highly specific
but less sensitive. In fact, 38% of melanomas scored less
than 3 points (in situ melanomas frequently only scored
1 point) using the checklist and were identified
only thanks to additional information such as anamnestic
data, the ugly-duckling sign and signature nevi [7,23] or
changes at digital follow-up [24]. Regression patterns,
atypical vascular patterns and radial streaming were
associated with the highest relative risk for melanoma [7].
Argenziano et al. revised the 7-point checklist, reducing
theoriginal3-pointthresholdto1-pointinordertoidentify
more melanomas. This gave higher mean rates of excision
with an increased sensitivity but a lower specificity
compared with the original 7-point checklist and pattern
analysis. The authors recommend using the revised
algorithminadailyclinicalsetting,integratingdermoscopy
with clinical information and follow-up [20].
Borsarietal.recentlydescribedanewmelanomapredictor,
the dermoscopic island [25], which differs from the
eccentric pigmentation described by Arevalo et al. [26].
The dermoscopic island is defined as a circumscribed area
showing a different dermoscopic pattern from the rest of
the lesion (reticular, globular, homogeneous or starburst
pattern) located at the periphery or in a paracentral
position. It is more frequently observed in in situ and thin
melanomasthaninnevi,andrepresentsthemorphological
aspect of initial malignant transformation. Lesions
showing this feature should be referred for excision [25].
Eccentric pigmentation represents an area of asymmetrical
pigment distribution and lesions showing this feature, but
lacking other specific criteria for melanoma, do notrequire
closer follow-up than other nevi [26].
The use of polarized light in dermoscopy allows the
recognition of some structures not visible with non-
polarized light [8,27,28]. Shiny white streaks arranged in
an orthogonal organization are known as chrysalis
structures [29,30]. Some authors proposed changing this
term to crystalline structures, to include short white lines,
white strands, white clods or white areas and rosettes [31].
Short white lines arranged in an orthogonal fashion may
beobservednotjustinmelanomasandSpitznevibutalso
in basal cell carcinomas, squamous cell carcinomas and
dermatofibromas [29,31,32].
Argenzianoetal.[33]describedanewpredictorofnodular
melanoma,theblue-blackcolorduetothecombinationof
pigment localized in the mid-deep dermis (blue) and, in
atypicalmelanocytes,intheepidermis(black).Theauthors
found a higher sensitivity for blue-black color with respect
to standard criteria in the diagnosis of nodular melanoma
(78.2% vs 43.6% respectively). Combination of the two
reaches 84.6% sensitivity with 80.5% specificity. The blue-
blackcolorisausefulnewfeatureallowingthediagnosisof
some melanomas lacking standard criteria.
Few studies have been performed on hypopigmented
lesions. Menzies et al. [34] looked at hypomelanotic and
amelanoticmelanomaandfoundblue-whiteveil,scar-like
depigmentation,multipleblue-graydots,irregular-shaped
depigmentation, brown dots/globules irregular in size or
distribution, five to six colors and predominant central
vessels to be the most positive predictors of melanoma. In
contrast, three or more milia-like cysts, comma vessels
with regular distribution or the predominant vessel type,
symmetrical pigment distribution, irregular or multiple
blue-gray globules are the most significant negative
predictive factors in melanoma diagnosis [34]. Accuracy
of dermoscopic criteria is lower for hypomelanotic-
amelanotic melanoma than with pigmented melanoma,
but still superior to naked-eye examination [34].
Advances in digital follow-up
Sequential digital dermoscopy imaging (SDDI) is crucial in
identifying melanomas lacking the specific criteria of
malignancy. Unlike long-term follow-up (6-12 months),
any morphologic change detected on short-term 3-month
follow-up serves as a reliable prompt for the physician
to excise the lesion. In contrast, lesions not showing
dermoscopic changes on follow-up imaging can be left to
avoidunnecessaryexcision[24,35,36].Three-monthfollow-
up remains the correct interval (rather than 6 weeks) to
diagnose featureless melanoma [35]. Three months is also
the recommended follow-up period for high-risk patients,
such as those with familial atypical mole and multiple
melanoma (FAMMM)syndrome,but6-12 monthsisbetter
for those with atypical mole syndrome [37,38].
Short-term follow-up is also the best strategy to optimize
patient compliance. Patients addressed to a short-term
follow-up are more likely to return compared with long-
term follow-up patients, probably because of the major
concern about a lesion to be checked after only 3 months
[36]. Unfortunately, not all melanomas are clearly
detected at 3-months follow-up. Sometimes long-term
follow-up visits are needed to detect suspect changes [39].
Argenzianoetal.[39]describedaseriesof103melanomas
diagnosed and excised after long-term follow-up with
Page 2 of 6
(page number not for citation purposes)
F1000 Medicine Reports 2012, 4:11 http://f1000.com/reports/m/4/11minimal dermoscopic changes, with respect to the base-
line visit (mean follow-up time: 20 months) and still
in situ or thin at the time of histopathological diagnosis.
Melanomas showing a reticular pattern on baseline image
aremorelikelytoremaininsitu,whereasthosewithanon-
reticular pattern usually show major changes at follow-up
control.Thissupportsthetheorythatmelanomarepresent
af a m i l yo ft u m o r s :r a p i d l yg r o w i n gm e l a n o m a sw i t ha
high capacity to metastasize, on the one hand, and slowly
growing lesions often detectable only after repeated
follow-up visits, on the other. Correct use of SDDI allows
us to increase diagnostic accuracy, and reduce the number
of undetected melanomas and also unnecessary excisions
[24,38].
Advances in understanding melanocytic nevi
and nevogenesis
Dermoscopy also allows us to study the physiology of
nevi (clusters of pigmented skin cells). Some people have
a high propensity to develop nevi, others lower, and this
propensity is genetically established and, in part, due to
environmental factors. The number of nevi is small in
childhood, increases during adolescence and mid-life,
and finally decreases during late adulthood [40-42]. The
dermoscopic pattern of nevi seems to be age- and site-
related, with a prevalence of globular nevi on the trunk
in childhood (which tend to persist), and reticular nevi
appearing on the upper back and extremities in adult-
hood (which tend to fade over time) [40,41,43,44].
These data led Zalaudek et al. to prepare two different
pathways for nevogenesis [40,45]: the constitutional
pathway gives rise to congenital globular nevi in child-
hood; and the acquired pathway is responsible for arising
nevi with a prevalent reticular pattern in adolescence and
adulthood. Based on these and other observations,
Argenziano et al. proposed a new dermoscopic classifica-
tion of melanocytic nevi into seven groups based on
specific dermoscopic features that identify those lesions as
specific entities (Table 1) [46].
Spitz/Reed nevi received particular attention. The original
clinical description of a pink-red papulonodular lesions
on the face and extremities of children or black (Reed
nevus) papules or plaques on the extremities is no longer
optimal for diagnosis [47,48]. Dermoscopy completely
changed this view by identifying three main dermoscopic
patterns: globular, starburst and multicomponent (atypi-
cal, melanoma-like) [48,49]. Similar to acquired nevi,
Spitz/Reed nevi follow an evolution/involution process
[50]. In the evolution, or growing phase, Spitz/Reed nevi
show the classical starburst pattern, which is subsequently
replaced after a variable number of months by a
homogenous pattern observed during the stability phase.
After some years, lesions gradually lose pigment and
finally disappear, indicating that involution is common
[50]. However, the recommendation is to excise nevi with
spitzoid features in patients older than 12 years [48].
The BRAF oncogene is highly expressed in acquired nevi,
whereas other types of melanocytic nevi – such as
congenital dermal nevi, Spitz, and blue nevi – are usually
characterized by mutations in other genes. BRAF muta-
tions induce melanocyte proliferation, forming neoplastic
Table 1. Nevus dermoscopic subtypes
Nevus type Clinical features Dermoscopic features
Globular (congenital) nevus Present at birth or appearing before
puberty
Globular pattern in children; cobblestone or fried-egg pattern in adults
Reticular (acquired) nevus Onset after puberty or in adulthood Reticular pattern with or without hypopigmented or structureless area.
Occasionally atypical features
Starburst (Spitz/Reed) nevus Onset mostly during childhood or
adolescence
Peripheral pigmented streaks or globules symmetrically distributed. Dotted
vessels and reticular depigmentation in non-pigmented lesions
Blue (homogeneous) nevus Congenital or acquired Homogeneous structureless blue coloration. Sometimes white areas of fibrosis
or hypomelanosis
Site-related nevi
a. Acral nevus Congenital or acquired Parallel furrow, lattice-like, fibrillar pattern and other minor patterns
b. Facial nevus Congenital or early-acquired Children: pseudoreticular pattern
Adults: remnants of pigmentation and comma vessels
Nevi with special features
a. Combined nevus Congenital or acquired Combination of two or more patterns: reticular, globular, homogeneous and
starburst
b. Halo nevus Congenital or acquired Globular pattern with blue granules and/or with scar-like areas
c. Irritated nevus Congenital or acquired Reticular, globular or structureless with variable grey or red areas
d. Nevus with eczematous halo Congenital or acquired Reticular, globular or structureless with yellowish areas
c. Recurrent nevus Congenital or acquired (previous
excision or trauma)
Atypical pigmentation and scar-like areas
Unclassifiable melanocytic
lesions
One of the previous nevi with
atypical features
One of the previous patterns with atypical features. Melanoma cannot be
ruled out
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induced by intermittent UV exposure, proliferation stops
and cells enter a senescent phase[40].BRAF mutations are
probably acquired early in nevogenesis and their level of
expression is correlated with the phase of growth [51].
Based on this theory, it seems that young benign reticular
nevi express high levels of BRAF mutations, slowly
decreasing with nevus growth, followed by a final low
rate in senescence [40].
Conclusions
Dermoscopy has dramatically improved the diagnostic
accuracy of melanocytic skin lesions and, more recently, is
helping us understand nevogenesis mechanisms and
nevus physiology. New advances in terms of optimal
application and follow-up and newly described criteria
have gradually allowed us to correctly diagnose mela-
noma even in very early stages, where rates of curability
andsurvivalarehigh.Thissuccessmaybean argumentfor
a more widespread application of dermoscopy to screen
the wider asymptomatic community on a routine basis.
Abbreviations
FAMMM, familial atypical mole and multiple mela-
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